The 50th Annual Meeting of the American Society of Clinical Oncology took place May 30 – June 3 in Chicago, Illinois.

Ruxolitinib improves disease control in PV



ASCO_2014_attendees_ASCO_Phil McCarten_230.jpg
Session at ASCO 2014
©ASCO/Phil McCarten

The JAK1/2 inhibitor ruxolitinib may be a “valuable new treatment option” for patients with polycythemia vera (PV) who cannot tolerate or are resistant to hydroxyurea, according to a speaker at the 2014 ASCO Annual Meeting. Results of the phase 3 RESPONSE trial showed that ruxolitinib can... [Read Article]

Treating HIV+ lymphoma patients



ASCO_2014_stairs_ASCO-Brian_Powers_230.jpg
Attendees at ASCO 2014
©ASCO/Brian Powers

Hepatitis C reactivation does not worsen survival outcomes for HIV-positive patients diagnosed with lymphoma, new research indicates. The study showed these patients can tolerate chemotherapy without adverse outcomes and are therefore eligible for aggressive treatment. They should be closely monitored, however, according to study investigator Stefan K. Barta,... [Read Article]

Elderly males with DLBCL require increased rituximab dosing



ASCO_attendees_theatre_ASCO_Phil_McCarten_230.jpg
Attendees at ASCO 2014
©ASCO/Phil McCarten

Elderly males with non-Hodgkin lymphoma (NHL) may require one-third higher doses of rituximab than the current standard to attain optimal responses to rituximab-containing chemotherapy, a new study suggests. Increasing the rituximab dose eliminated any gender-related differences in survival among elderly patients with aggressive, CD20+, B-cell lymphomas, said investigator... [Read Article]

Switch to nilotinib improves deep molecular response in CML



audience_ASCO_2014_Credit_ASCO_hil_McCarten_230.jpg
Audience at ASCO 2014
©ASCO/Phil McCarten

Patients with chronic myeloid leukemia (CML) are more likely to achieve a deep molecular response if they switch to nilotinib rather than remain on imatinib, updated research suggests. Patients with detectable disease who crossed over from imatinib to nilotinib after 24 months on the ENESTcmr study were able... [Read Article]

CNS involvement predicts relapse but not survival in ARL, study shows



ASCO_2014_posters_ASCO-Todd Buchanan_230.jpg
Posters at ASCO 2014
©ASCO/Todd Buchanan

Investigators have found evidence to suggest that identifying central nervous system (CNS) involvement at diagnosis does not impact overall survival for patients with AIDS-related lymphoma (ARL). The research showed that ARL patients with CNS involvement at diagnosis were nearly 3 times as likely as their peers... [Read Article]

CAR T-cell therapy successfully used frontline as consolidation in CLL



ASCO_2014__posters_Credit ASCO-Todd Buchanan 2014_230.jpg
Poster hall at ASCO 2014
©ASCO/Todd Buchanan

Infusion of autologous CD19-targeted chimeric antigen receptor (CAR)-modified T cells appears to have promising anti-tumor activity and be well-tolerated as a consolidation to frontline chemotherapy in patients with high-risk chronic lymphocytic leukemia (CLL), researchers report. In a phase 1 trial, the... [Read Article]

Lenalidomide combination improves QOL in newly diagnosed MM



ASCO_2014_Info booth_Credit ASCO-Scott Morgan 2014_230.jpg
Info booth at ASCO 2014
© ASCO/Scott Morgan

Substituting lenalidomide for thalidomide in the standard treatment of newly diagnosed multiple myeloma (MM) improves quality of life and lowers toxicity without significant loss of response, results of a phase 3 study suggest. Combination melphalan, prednisone, and thalidomide... [Read Article]

Novel agent shows promising activity in heavily pretreated NHL



ASCO_2014_Lobby_Credit ASCO-Rodney White 2014_230.jpg
Lobby view at ASCO 2014
©ASCO/Rodney White

The novel, oral selective inhibitor of nuclear transport known as selinexor (KPT-330) can safely be given as monotherapy to patients with heavily pretreated non-Hodgkin lymphoma (NHL), according to a presentation at the 2014 ASCO Annual Meeting. “Selinexor has favorable pharmacokinetic... [Read Article]